Logo

Chris van Ingen

Jun 28, 2017

Chris van Ingen, a former member of Bruker's board of directors, died on June 27, Bruker said in a document filed with the US Securities and Exchange Commission. van Ingen died less than a week after he told the firm that he would be retiring from the board due to medical reasons. The cause of his death was not disclosed. He had been on Bruker's board since 2012. From 2001 to 2007, van Ingen was with Agilent Technologies where he served as president of the firm's bio-analytical measurement business.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.